| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.041 | 0.5 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.043 | 0.5 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |